LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Longeveron Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.39+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $43.61M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
67.0%+34.5 pts over 5 years
Operating margin
-1942.2%−1875.1 pts over 5 years
Net margin
-1893.6%−1827.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -49.9% | -0.6% | -26.6% | – | |
| Gross profit | -57.4% | +17.3% | -15.2% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -379.4% | -164.7% | |
| Return on assets | – | – | -126.8% | |
| Current ratio | – | 0.48 | 1.33 | |
| Interest coverage | – | -539.7× | – | |
| Capex to revenue | – | 2.3% | 20.4% | |
| Diluted shares | – | 2M | 17.58B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Longeveron generated $75.12M from operations and spent $2.10M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$75.12M
Used
$2.10M
Capital expenditure$2.10M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1893.6%
×Asset turnover0.07×
×Equity multiplier1.30×
=Return on equity, FY2025-164.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1893.6% | 0.07× | 1.30× | -164.7% |
| FY2024 | -667.8% | 0.13× | 1.31× | -111.6% |
| FY2023 | -3020.2% | 0.04× | 1.45× | -157.2% |
| FY2022 | -1541.3% | 0.03× | 1.21× | -65.0% |
| FY2021 | -1305.1% | 0.05× | 1.32× | -86.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$22.70M
- Cash generatingOperating cash flow above zero-$18.65M
- Return on assets improvedROA up on the prior year-132.2% → -88.8%
- Earnings backed by cashOperating cash flow above net income-$18.65M vs -$22.70M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.60 → 1.33
- No dilutionShare count did not rise9.41B → 17.58B
- Gross margin improvedGross margin up on the prior year78.76% → 66.97%
- More efficientAsset turnover rose0.20 → 0.05